- Thursday, 30 July 2015
- AstraZeneca PLC second quarter and half year results 2015 Visit our global site to view full details of the event.
- Monday, 13 July 2015
- IRESSA® (gefitinib) approved by the U.S. Food and Drug Administration for first-line treatment of advanced EGFR mutation-positive non-small cell lung cancer AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved IRESSA® (gefitinib) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
- Wednesday, 8 July 2015
- AstraZeneca celebrates more than 35 years of ongoing patient support through its patient assistance programs AstraZeneca is pleased to announce our ongoing support for patients through our longstanding patient assistance programs. In 2014 alone, the AZ&Me Prescription Savings Programs provided more than $670 million in savings to nearly 383,000 patients in the United States.
- Saturday, 13 June 2015
- AstraZeneca announces Phase III results for lesinurad in combination with febuxostat in tophaceous gout patients at European League Against Rheumatism Annual Congress (EULAR 2015) AstraZeneca today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. Lesinurad works in combination with febuxostat to provide a dual mechanism of action which increases excretion and decreases production of uric acid.
- Tuesday, 2 June 2015
- AstraZeneca updates on immuno-oncology combinations development program at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 1, 2015.
- Sunday, 31 May 2015
- AstraZeneca presents positive data on AZD9291 in first-line EGFR mutated lung cancer at ASCO 2015 AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC). Data showed that 81% (95% confidence interval (CI) 68% to 89%) of patients on a once daily dose of AZD9291 were progression free at 9 months; overall response rate was 73% (95% CI 60% to 84%). The longest duration of response was ongoing at 13.8 months at the time of data cutoff.
- Saturday, 30 May 2015
- AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015 AstraZeneca and MedImmune, AstraZeneca’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
- Wednesday, 20 May 2015
- Olympic gold medalist Jackie Joyner-Kersee teams up with AstraZeneca to raise awareness about opioid-induced constipation AstraZeneca and Daiichi Sankyo, Inc. today announced that they have partnered with six-time Olympic medalist Jackie Joyner-Kersee to increase awareness of opioid-induced constipation (OIC).
- Saturday, 16 May 2015
- MOVANTIK™ (naloxegol) safety analyses of opioid-induced constipation patients 65 and older with chronic non-cancer pain Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies presented today at Digestive Disease Week (DDW) 2015 in Washington, D.C. showed that MOVANTIK™ (naloxegol) had a similar incidence of adverse events (AEs) among elderly patients as compared to placebo or usual care. The study evaluated the effects of daily oral administration of MOVANTIK 12.5 mg or 25 mg vs placebo among outpatients 65 years and older with opioid-induced constipation (OIC) and chronic non-cancer pain.
- Wednesday, 13 May 2015
- AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.